Altimmune, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALT research report →
Companyaltimmune.com
Altimmune, Inc. , a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.
- CEO
- Jerome Benedict Durso
- IPO
- 2017
- Employees
- 59
- HQ
- Gaithersburg, MD, US
Price Chart
Valuation
- Market Cap
- $246.68M
- P/E
- -3.82
- P/S
- 6852.20
- P/B
- 1.22
- EV/EBITDA
- -1.98
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -41519.44%
- Op Margin
- -269216.67%
- Net Margin
- -253002.78%
- ROE
- -42.57%
- ROIC
- -29.86%
Growth & Income
- Revenue
- $41.00K · 105.00%
- Net Income
- $-88,093,000 · 7.33%
- EPS
- $-1.00 · 25.37%
- Op Income
- $-94,489,000
- FCF YoY
- 15.41%
Performance & Tape
- 52W High
- $7.73
- 52W Low
- $2.56
- 50D MA
- $3.20
- 200D MA
- $3.97
- Beta
- 0.17
- Avg Volume
- 3.99M
Get TickerSpark's AI analysis on ALT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | Lawver Teri L | other | 48,800 |
| May 1, 26 | Sohn Catherine A. | other | 48,800 |
| May 1, 26 | Jorkasky Diane | other | 48,800 |
| May 1, 26 | Schafer Klaus | other | 48,800 |
| May 1, 26 | Pisano Wayne | other | 48,800 |
| May 1, 26 | Hodges Philip | other | 48,800 |
| May 1, 26 | GILL JOHN | other | 48,800 |
| May 1, 26 | SAYARE MITCHEL | other | 48,800 |
| Apr 6, 26 | GILL JOHN | buy | 9,200 |
| Apr 1, 26 | WEAVER GREGORY L | buy | 10,000 |
Our ALT Coverage
We haven't published any research on ALT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALT Report →